Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer

BackgroundTo accelerate drug approvals while maintaining scientific rigor in the evaluation of a therapeutic's efficacy and safety, the United States Food and Drug Administration now considers real-world data (RWD) to support New Drug Applications and expanded indications. Response Evaluation Criteria in Solid Tumors (RECIST) are the gold standard in clinical trials, but the derivation of RECIST-based treatment response from RWD is unproven. This study investigated the feasibility of implementing RECIST criteria in RWD by comparing lung cancer response assessments from RECIST-based measurement of lesions on archived radiologic films with results from medical oncologist and radiologist narratives recorded in electronic health records (EHR).Materials and MethodsResponse to index treatment via different assessment approaches was compared among 30 metastatic non-small cell lung cancer (mNSCLC) patients receiving systemic treatment (index) after progression on a platinum or anti-PD(L)-1-containing regimen. Specifically, responses based on assessments documented in the medical oncologists’ narratives were compared to a radiologist's assessments of archived images using RECIST v1.1 criteria. Each patient's best overall response was characterized as complete or partial (CR/PR), stable disease (SD), progressive disease (PD), or not evaluable (NE).ResultsSimilar distributions of best overall response and substantial concordance (77%) between medical oncologist-reported and radiologist re-assessed responses were observed. There were no instances of CR/PR to PD or PD to CR/PR discordance.ConclusionsResults suggest that accurate treatment responses, similar to RECIST, may be derived using RWD. Further validation and improvement of real-world response assessment are needed to develop a scalable real-world approach for response assessment.     

Delayed haemolytic transfusion reaction due to Kidd antibodies

A delayed haemolytic transfusion reaction (DHTR) encompasses a positive direct antiglobulin test (DAT) developed anytime between 24 hours to 28 days after cessation of transfusion, a positive eluate or a newly identified alloantibody in the plasma or serum along with features of haemolysis in the patient. Routinely, it is expected that with the transfusion of one unit of packed red cells in a patient of average height and weight, the haemoglobin level and hematocrit increase by 1 g/dL and 3% respectively. However, in a patient with DHTR, an inadequate rise of post-transfusion haemoglobin (< 1 g/dL) or rapid fall in haemoglobin back to pre-transfusion levels is observed. Kidd antibodies are particularly known to cause DHTR, maybe alone or in unison with other antibodies. Detection of these alloantibodies is consequential in providing good transfusion support to these patients. These events may be difficult to detect as they may present as varied clinical features or immunological nuisances. In this case series, we have presented three cases of DHTR with special emphasis on their clinical presentations, immunohaematological evaluations, laboratory parameters and the role of proper transfusion support in these patients to avoid further complications.     

Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals,a prospective longitudinal cohort study

PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals.     

Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection

1. Download : Download high-res image (90KB)
2. Download : Download full-size image

     

Pan-cancer proteomic map of 949 human cell lines

1. Download : Download high-res image (220KB)
2. Download : Download full-size image

     

以患者为中心的护理模式在腹腔镜胆囊切除术中的应用及对患者应激反应的影响

目的 探讨以患者为中心的护理模式在腹腔镜胆囊切除术中的应用效果及对患者应激反应的影响。方法 选取2019年3月至2021年3月于我院行腹腔镜胆囊切除术的64例患者,按照入组单双顺序平均分为观察组(以患者为中心的护理模式)与对照组(常规急诊护理)各32例。比较两组的生理应激反应、心理应激反应和术后恢复情况。结果 干预后,观察组的胰岛素、皮质醇水平及HAMA、 HAMD评分低于对照组,肾上腺素水平高于对照组(P<0.05)。观察组的VAS评分低于对照组,肛门排气及下床活动时间短于对照组(P<0.05)。结论 以患者为中心的护理模式可减轻急诊胆囊切除术患者的生理及心理应激反应,促进患者术后康复。     

刺槐素通过调控TLR4通路对干眼症大鼠的保护作用及其机制研究＊

目的 研究刺槐素对干眼症（DED）大鼠的保护作用及可能的分子机制。方法 60只SD大鼠随机分为空白组（不做处理）；模型组；0.1% SH组；刺槐素0.1%、0.25%、0.5%组。每组10只，除正常组外，每日4次皮下注射12.5 mg/天氢溴酸东莨菪碱（SCOP），共7天。所有的药物均为在眼球表面局部给药，每只眼睛20 μL，每天4次。通过泪液分泌实验检测各组大鼠泪液分泌情况，通过角膜荧光染色检测各组大鼠角膜表面缺损情况，过碘酸雪夫试剂（PAS）染色观察结膜杯状细胞数量，酶联免疫吸附法（ELISA）检测各组大鼠角膜组织中炎症反应和氧化应激相关指标含量。免疫印迹法（Western blot）检测各组大鼠角膜组织中Toll样受体4（TLR4）通路相关蛋白TLR4、髓样分化因子88（MyD88）、核因子κB p65（NF-κB p65）、Pyrin域蛋白3（NLRP3）蛋白表达。结果 与正常组相比，模型组大鼠泪液分泌量、结膜杯状细胞数量明显减少，角膜荧光素染色评分显著升高，但角膜新血管生成评分减少，同时角膜组织中白细胞介素1β（IL-1β）、肿瘤坏死因子α（TNF-α）、IL-10、丙二醛（MDA）水平上调，而超氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）含量则下调，TLR4、MyD88、NLRP3、p-NF-κB p65蛋白相对表达量均升高（P<0.05）；与模型组相比，经刺槐素0.25%、0.5%组治疗后，大鼠泪液分泌量、结膜杯状细胞数量明显增加，角膜荧光素染色评分显著降低，角膜新血管生成评分显著增加，同时角膜组织中IL-1β、TNF-α、IL-10、MDA水平下调，而SOD和GSH-Px含量则上调（P<0.05），尤其是刺槐素0.5%组上述指标变化更明显，而且角膜组织中TLR4、MyD88、NLRP3、p-NF-κB p65蛋白相对表达量较模型组显著降低（P<0.05）。结论 刺槐素对干眼症大鼠具有保护作用，其保护机制与抑制干眼症大鼠的氧化应激反应、炎症反应和TLR4/MyD88/NLRP3通路活性有关。     

Methodological advances in the design of peptide-based vaccines

The tremendous advances in genomics, recombinant DNA technology, bioengineering and nanotechnology, in conjunction with the development of high-end computations, have been instrumental in the process of rational design of peptide-based vaccines. The use of peptide vaccines was limited owing to their inherent instability when systemically administered; however, advanced formulation techniques have been developed for their systemic delivery, thereby overcoming their degradation, clearance, cellular uptake and off-target effects. With the rise of sophisticated immunological predictors and experimental techniques, several methodological advances have occurred in this field. This review examines contemporary methods to identify and optimize epitopes, engineer their immunogenic properties and develop their safe and efficient delivery into the host.